American Century Companies Inc. Has $8.83 Million Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

American Century Companies Inc. cut its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCRFree Report) by 16.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 510,201 shares of the company’s stock after selling 102,415 shares during the period. American Century Companies Inc. owned about 0.89% of Structure Therapeutics worth $8,832,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GPCR. Deep Track Capital LP grew its stake in shares of Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after purchasing an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Structure Therapeutics by 50.0% in the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Structure Therapeutics in the fourth quarter worth $13,560,000. Ameriprise Financial Inc. grew its stake in shares of Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company’s stock worth $38,512,000 after purchasing an additional 322,601 shares during the last quarter. Finally, Baker BROS. Advisors LP boosted its position in Structure Therapeutics by 322.9% during the fourth quarter. Baker BROS. Advisors LP now owns 361,565 shares of the company’s stock valued at $9,806,000 after acquiring an additional 276,065 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, June 23rd. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 price target on the stock. JMP Securities cut their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. HC Wainwright cut their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Finally, Guggenheim cut their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and an average price target of $75.71.

Check Out Our Latest Report on GPCR

Structure Therapeutics Price Performance

GPCR stock opened at $18.82 on Wednesday. The stock has a market capitalization of $1.08 billion, a PE ratio of -17.92 and a beta of -1.89. The company’s 50-day moving average is $19.16 and its 200-day moving average is $20.95. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $13.22 and a 1 year high of $45.37.

Structure Therapeutics (NASDAQ:GPCRGet Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). On average, analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

(Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

See Also

Institutional Ownership by Quarter for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.